37 results about "DNA Microarray Chip" patented technology

The invention relates to information security technology, in particular to a virtual genome-based cryptosystem (VGC). The cryptosystem is provided with two matched keys, of which one is a virtual genome database (VGDB) consisting of random deoxyribonucleic acid (DNA) sequences and the other one is a position table that virtual genes of the VGDB are randomly distributed in a two-dimensional microarray, namely a virtual DNA microarray chip (VDMC). Any plaintext information can be freely written on the VDMC, namely points for forming the plaintext information are selected from the VDMC microarray. The selected points correspond to the virtual genes in the VGDB; small segments of DNA sequences are randomly selected from the virtual genes; and the uniqueness of the small segments of DNA sequences in the VGDB is determined by using a common tool of the bioinformatics, namely a basic local alignment search tool (BLAST), or other character string search algorithms such as a Knuth-Morris-Pratt (KMP) algorithm and the like. A cipher text is combined by the small segments of DNA sequences. The small segments of DNA sequences need only to perform BLAST on the VGDB during decryption, namely the points for forming the plaintext information can be discovered, and the plaintext information can be restored according to the VDMC. Any non-VGDB sequence can be randomly inserted into the cipher text and does not have any influence on the encryption. Thus, the VGC is an excellent information hiding system. In addition, the VGC key can be updated automatically so as to realize an indecipherable one-time-pad system. The cryptosystem is used for real-time quick secret information communication, digital signature and identity authentication.

A process for high-flux screening, capturing and separation of target moleculae from complex substance (Chinese medicine or chemical mixer) includes preparing a ds DNA microarray chip to make its probe have a binding sites of dsDNA bindin, measuring the affinity of the sites, creating the standard affinity parameter system, mixing the microarray chip with said complex substance, reacting, detecting the affinity variation, screening the varied targets, linking them to the surface of chromatographic column, filling the complex substance in it, capturing the effective moleculae by probes, eluting and collecting the effective moleculae.

The invention discloses a process for preparing DNA micro array chips based on gel fixed nucleic acid, which comprises mixing acrylamide modified nucleic acid, acrylamide monomer, ammonium peroxodisulfate, glycerin and water into pre-polymer, wherein the concentration of the nucleic acid is between 0.001-100uM, the monomer weight concentration of acrylamide is between 1-30%, the weight concentration of the ammonium peroxodisulfate is between 0.01-5%, the weight concentration of glycerin is between 10-50%, then applying the sample of the prepolymer onto a solid substrate, loading the sample applying substrate into an airtight case containing tetramethylethylenediamine, so as to make the tetramethylethylenediamine volatilize.

The invention discloses a DNA micro-array chip and a detection method thereof and the application on detecting the polymorphism of CYP3A4, CYP3A5 and MDR1 genes. The chip comprises a solid phase carrier and a probe. The nucleotide sequence of the probe is shown as SEQ ID No: 1-SEQ ID No: 49. The probe is firstly arranged on the solid phase carrier. And then the target nucleotide sequence of a sample to be detected is marked and prepared. After that, the target nucleotide sequence is hybridized with the probe on the chip. Finally, the hybridization result is detected to obtain the information of the CYP3A4, CYP3A5 and MDR1 genes in the sample to be detected. The chip of the invention can be used for the detection of a plurality of genes of a plurality of samples simultaneously once only and has the advantages of simple operation and high result accuracy. Large amount of genetic information of patients can be obtained through detection once. The DNA micro-array chip and the detection method thereof can be used for instructing the formulation of reasonable drug schemes and realizing the personalized medical treatment.

The invention relates to a DNA microarray chip, in particular to a hepatitis C virus (HCV) genotyping DNA microarray chip. A solid-phase carrier substrate is used, and an oligonucleotide probe is designed in view of different genotypes of HCV so as to prepare the DNA microarray chip; and when matched with a PCR primer and other components, the DNA microarray chip can quickly and accurately classify the types of the hepatitis C virus in a blood sample.

The present invention relates to a biomarker for the identification of specific exposure to lower aliphatic saturated aldehydes which are volatile organic compounds exposed in the environment, and a method for the identification of specific exposure to lower aliphatic saturated aldehydes using the same, precisely a biomarker which is up- or down-regulated specifically by lower aliphatic saturated aldehyde exposure and a method for the identification of specific exposure to lower aliphatic saturated aldehydes using the biomarker. The biomarker of the present invention is the reacted genes selected by using DNA microarray chip, which can be effectively used for the monitoring and evaluation of lower aliphatic saturated aldehyde contamination in the environment samples and at the same time as a tool for the investigation of the toxic mechanism induced specifically by lower aliphatic saturated aldehydes.

The present invention provides a novel DNA microarray chip that can be used for simultaneous testing of transcriptional responses to cutaneous stressors in the context of neuro-endocrine-immune functions of the skin. The transcriptional responses to ultraviolet radiation in epidermal keratinocytes were tested using such microarray chip containing more than 700 neuro-endocrine-immune related genes. The gene expression pattern was non-random and time dependent; it included increased expression of genes involved in water and salt balance, prostaglandin synthesis, keratinocyte differentiation as well as genes coding for stress effectors, cytokines and metalloproteinases. In contrast, expression was decreased for genes coding for growth factors and their receptors, and for elements of extracellular matrix. This stochastic pattern suggests that transcriptional responses are coordinated and aimed at preservation of epidermal barrier function, prevention of early carcinogenic events and remodeling of extracellular matrix.

The invention relates to information security technology, in particular to a virtual genome-based cryptosystem (VGC). The cryptosystem is provided with two matched keys, of which one is a virtual genome database (VGDB) consisting of random deoxyribonucleic acid (DNA) sequences and the other one is a position table that virtual genes of the VGDB are randomly distributed in a two-dimensional microarray, namely a virtual DNA microarray chip (VDMC). Any plaintext information can be freely written on the VDMC, namely points for forming the plaintext information are selected from the VDMC microarray. The selected points correspond to the virtual genes in the VGDB; small segments of DNA sequences are randomly selected from the virtual genes; and the uniqueness of the small segments of DNA sequences in the VGDB is determined by using a common tool of the bioinformatics, namely a basic local alignment search tool (BLAST), or other character string search algorithms such as a Knuth-Morris-Pratt (KMP) algorithm and the like. A cipher text is combined by the small segments of DNA sequences. The small segments of DNA sequences need only to perform BLAST on the VGDB during decryption, namely the points for forming the plaintext information can be discovered, and the plaintext information can be restored according to the VDMC. Any non-VGDB sequence can be randomly inserted into the cipher text and does not have any influence on the encryption. Thus, the VGC is an excellent information hiding system. In addition, the VGC key can be updated automatically so as to realize an indecipherable one-time-pad system. The cryptosystem is used for real-time quick secret information communication, digital signature and identity authentication.

The present invention relates to a screening method using the genes related to teratogenicity, more precisely the genes up- or down-regulated by a drug inducing teratogenicity such as thalidomide, valproic acid, and methotrexate and a method for screening of thalidomide, valproic acid and methotrexate using the genes. The genes of the present invention is based on reactive genes selected by DNA microarray chip, so that it is very effective in risk assessment and monitoring drugs or chemicals having high risk of teratogenicity and at the same time it can be used as a tool to examine mechanism of teratogenicity.

The invention relates to a gene detection kit used for clinical detection, in particular to the preparation and the usage of a micro-array chip used for HLA-B27 genotyping. A DNA micro-array chip technology is adopted, and the kit can carry out partign to human leucocyte antigen B27, with high pass, high efficiency and high specificity.

The invention relates to a DNA microarray chip, in particular to an HBV YMDD mutation, precore region mutation / BCP region mutation and genotyping integrated-detection DNA microarray genetic chip. A solid-phase carrier substrate is used, and an oligonucleotide probe is designed in view of the HBV YMDD mutation, the precore region / BCP region mutation sites and the HBV genotype so as to prepare the DNA microarray chip. The DNA microarray chip can simultaneously detect three indexes at one time and can simultaneously detect a plurality of samples. The DNA microarray chip can be widely used to individual medicine taking guidance in the clinical process of treating HBV infections.

The invention is to detect the DNA conjugated protein using the hybrid DNA micro-array slug of exonuclease to protect DNA probe. The process is: (a) preparing the combined protein with DNA probe, the vector PCR, Tag-DNA; (b) combining the combined protein with DNA probe and the DNA conjugated protein; (c) treating with the exonuclease; (d) PCR amplifying and marking; detecting the hybrid product of PCR and the Tag-DNA. The method can detect many kinds of the DNA conjugated protein simultaneously but not modifying and marking the protein.

The invention relates to a gene detecting kit that is used in clinical detection, in particular to a DNA microarray chip detecting kit, which can realize subtype detection of human leukocyte antigen DQB1(HLA-DQB1) gene in high flux, high efficiency and high specificity.

The invention relates to a genetic testing kit used for clinical detection, in particular to the preparation of a microarray chip and a method thereof for HLA-DR4 genotyping. By adopting a DNA microarray chip technology, the kit can carry out the genotyping to HLA DR4 gene, with high pass, high efficiency and high specificity.

The invention relates to a gene mutation detection kit for the GS (Gilbert syndrome) and belongs to the technical field of biology. The kit comprises DNA (deoxyribose nucleic acid) micro-array chips formed by fixing an acrylamide modified PCR (polymerase chain reaction) product and other components on a propylene group modified slide as well as 6 nucleotide probe parts. The kit adopts a DNA micro-array technology, is simple and convenient to operate, low in price and capable of being applied to screening and clinical auxiliary diagnosis of diseases related to the GS caused by gene mutation.

The invention relates to DNA microarray chips, in particular to DNA microarray chips under human papilloma virus (HPV) high-risk and low-risk subtype classification. A solid-phase carrier substrate is adopted and matched with oligonucleotide probes of each HPV subtype so as to prepare the DNA microarray chips, which can simultaneously detect the HPV high-risk and low-risk subtypes of multiple samples at one time in high sensitivity and high specificity, and can be widely applied into qualitative and subtype detection of HPV infection.

The invention relates to the technical field of gene polymorphism detection, and in particular relates to sequencing primers, a kit and a detection method for detecting CYP2C19 gene polymorphism, which aim at overcoming the defects that a DNA microarray chip method for detecting CYP2C19 gene polymorphism is long in consumed time, relatively high in cost and inflexible in use in the prior art. The sequencing primers provided by the invention comprise a CYP2C19*2 sequencing primer of which the 3'-end base sequence comprises -ccactatcattgattatttc-3', and further comprises a CYP2C19*3 sequencing primer of which the 3'-end base sequence comprises -ttgtaagcaccccct-3'. The kit provided by the invention is short in detection time, low in detection cost and flexible in use, and the detection method is easy in operation.

The invention relates to a gene detecting kit used for clinical detection, in particular to the kit which adopts a DNA micro-array chip and a dual-temperature hybridization probe to execute the detection and typing on human leukocyte antigen gene in a high-throughput, high-efficiency and high-specificity manner and the usage thereof.

The present invention relates to a screening method using the genes related to teratogenicity, more precisely the genes up- or down-regulated by a drug inducing teratogenicity such as thalidomide, valproic acid, and methotrexate and a method for screening of thalidomide, valproic acid and methotrexate using the genes. The genes of the present invention is based on reactive genes selected by DNA microarray chip, so that it is very effective in risk assessment and monitoring drugs or chemicals having high risk of teratogenicity and at the same time it can be used as a tool to examine mechanism of teratogenicity.

The invention relates to a DNA microarray chip, in particular to an integrated high-flux detection DNA microarray chip for hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus 1 (HIV-1). A solid-phase carrier substrate is used, and an oligonucleotide probe is designed in view of genes of HBV, HCV and HIV-1 so as to prepare the DNA microarray chip; and when matched witha PCR primer and other components, the DNA microarray chip can simultaneously detect the three viruses in a plurality of samples with high sensitivity and high specificity. The DNA microarray chip ismainly used for screening the virus nucleic acid in blood and blood products.

The invention provides a micro-array chip based on a sphere-brush double layer nano-structure substrate and a preparation method thereof. The preparation method of the micro-array chip has versatility, and has the advantages of convenient process and less equipment requirement, and is suitable for large batch production; the micro-array chip can realize the analysis detection of interacting between nucleotide and nucleotide, sugar and protein, and protein and protein, and has the advantages of simpleness, less sample consumption and high sensitivity. The experiment result shows that the sugar micro-array chip prepared by the method has the detection limit on biotin-modified castor-oil plant agglutinin-120 and biotin-modified concanavalin agglutinin being 1 ng / mL, and the DNA micro-array chip has the detection limit on target DNA being 0.1 nmol / L; the glycoprotein micro-array chip has the detection limit on the biotin-modified castor-oil plant agglutinin-120 being 0.3 ng / ml, and the antibody micro-array chip has the detection limit on the CY5-modified rabbit-anti-human antibody being 10 pg / mL.

The present invention relates to a biomarker for the identification of specific exposure to propionaldehyde which is one of volatile organic compounds exposed in the environment, and a method for the identification of specific exposure to propionaldehyde using the same, precisely a biomarker which is up-regulated or down-regulated specifically by propionaldehyde and a method for the identification of specific exposure to propionaldehyde using the biomarker. The biomarker of the present invention is the reacted genes selected by using DNA microarray chip, which can be effectively used for the monitoring and evaluation of propionaldehyde contamination in the environment samples and at the same time as a tool for the investigation of the toxic mechanism induced specifically by propionaldehyde.

The invention relates to a DNA microarray chip, in particular to an integrated high-flux detection DNA microarray chip for hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus 1 (HIV-1). A solid-phase carrier substrate is used, and an oligonucleotide probe is designed in view of genes of HBV, HCV and HIV-1 so as to prepare the DNA microarray chip; and when matched witha PCR primer and other components, the DNA microarray chip can simultaneously detect the three viruses in a plurality of samples with high sensitivity and high specificity. The DNA microarray chip ismainly used for screening the virus nucleic acid in blood and blood products.

The invention relates to a gene detecting kit used for clinical detection, in particular to the kit which adopts a DNA micro-array chip and a dual-temperature hybridization probe to execute the detection and typing on human leukocyte antigen gene in a high-throughput, high-efficiency and high-specificity manner and the usage thereof.

The invention relates to a method for detecting Type 2 diabetes related mononucleotide polymorphism by using a DNA (deoxyribonucleic acid) microarray chip, belonging to the technical field of DNA microarray chips. By using 6-oligonucleotide-modified gold nanoparticles as the markers in combination with 6 oligonucleotide probes for Type 2 diabetes detection, a microarray chip inspection method capable of simultaneously detecting 6 Type 2 diabetes related mutant sites is developed, thereby implementing the detection on DNA samples of simulated Type 2 diabetes and actual samples of Type 2 diabetes.

The invention relates to a gene detection kit used for clinical detection, in particular to the preparation and the usage of a micro-array chip used for HLA-B27 genotyping. A DNA micro-array chip technology is adopted, and the kit can carry out partign to human leucocyte antigen B27, with high pass, high efficiency and high specificity.

The invention relates to a gene test kit used for clinical detection, in particular to the preparation and the usage of a micro-array chip used for HLA-A genotyping. A DNA micro-array chip technology and a dual temperature hybridization method are adopted, and the kit can carry out parting to the HLA-A gene, with high pass, high efficiency and high specificity.

The invention relates to a gene detecting kit that is used in clinical detection, in particular to a DNA microarray chip kit, which can realize subtype detection of human leukocyte antigen C(HLA-C) gene in high flux, high efficiency and high specificity.